| Literature DB >> 32207884 |
Rui Yan1, Jinming Yu1, Tetsuya Tanimoto2,3, Akihhiko Ozaki2,3, Xinyuan Lu1, Beibei Che1, Yaxuan Zhang1, Panzhen Chen1, Jiwei Wang1.
Abstract
PURPOSE: Less is known about sexual attitudes of breast cancer survivors (BCSs) and its association with sexual activity and sexual dissatisfaction.Entities:
Keywords: breast cancer survivors; cross-sectional studies; sexual activity; sexual attitude; sexual satisfaction
Year: 2020 PMID: 32207884 PMCID: PMC7221310 DOI: 10.1002/cam4.2874
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Reporting of sexual activity, sexual dissatisfaction, and BC decreased their sexual activity frequency in relation to demographic characteristics
| Demographic characteristics | Total | Sexual activity | Sexual dissatisfaction | BC decreased their sexual activity frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) |
| AOR | N (%) |
| AOR | N (%) |
| AOR | ||
| All | 341 | 83 (24.3) | 81 (23.8) | 201 (58.9) | ||||||
| Age (y) | ||||||||||
| Mean [SD](range) | 58.64 [6.61] (30‐75) | |||||||||
| <55 | 86 (25.2%) | 38 (44.2) | Ref | 25 (29.1) | Ref | 57 (66.3) | Ref | |||
| 55‐64 | 191 (56.0%) | 35 (18.3) |
| 43 (22.5) | 0.66 (0.36, 1.21) | 116 (60.7) | 0.73 (0.42, 1.26) | |||
| ≥65 | 64 (18.8%) | 10 (15.6) |
|
| 13 (20.3) | .382 | 0.57 (0.25, 1.28) | 28 (43.8) |
|
|
| Marital status | ||||||||||
| Married/cohabiting | 308 (90.3%) | 77 (25.0) | Ref | 69 (22.4) | Ref | 182 (59.1) | Ref | |||
| Single/separated/divorced/widowed | 33 (9.7%) | 6 (18.2) | .386 | 0.84 (0.32, 2.23) | 12 (36.4) | .073 | 2.06 (0.94, 4.54) | 19 (57.6) | .867 | 0.93 (0.44, 1.96) |
| Education | ||||||||||
| <High school | 198 (58.1%) | 51 (25.8) | Ref | 52 (26.3) | Ref | 127 (64.1) | Ref | |||
| High school | 118 (34.6%) | 25 (21.2) | 0.97 (0.54, 1.75) | 21 (17.8) | 0.59 (0.32, 1.07) | 64 (54.2) |
| |||
| >High school | 25 (7.3%) | 7 (28.0) | .596 | 1.01 (0.36, 2.79) | 8 (32.0) | .139 | 1.73 (0.66, 4.53) | 10 (40.0) |
|
|
| Household per capita income (yuan/mo) | ||||||||||
| <2000 | 60 (17.6%) | 17 (28.3) | Ref | 13 (21.7) | Ref | 38 (63.3) | Ref | |||
| ~2000 | 161 (47.2%) | 38 (23.6) | 0.86 (0.42, 1.75) | 42 (26.1) | 1.19 (0.57, 2.50) | 90 (55.9) | 0.71 (0.38, 1.34) | |||
| ≥4000 | 120 (35.2%) | 28 (23.3) | .729 | 0.75 (0.36, 1.58) | 26 (21.7) | .623 | 1.09 (0.51, 2.39) | 73 (60.8) | .530 | 0.88 (0.45, 1.79) |
All models were adjusted for age, marital status, self‐reported general health status, and time since cancer diagnosis.
Bold face P < .05.
Abbreviations: AOR, adjusted odds ratio; BC, breast cancer.
Chi‐square test or Fisher's exact test.
The 86 individuals in <55 age group include 5 individuals <45 y and 81 individuals 45‐54 y.
Reporting of sexual activity, sexual dissatisfaction, and BC decreased their sexual activity frequency in relation to general health and cancer‐related conditions
| Total | Sexual activity | Sexual dissatisfaction | BC decreased their sexual activity frequency | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) |
| AOR | N (%) |
| AOR | N (%) |
| AOR | ||
| General Health | ||||||||||
| BMI (kg/m2) | ||||||||||
| Underweight (<18.5) | 9 (2.6%) | 1 (11.1) | Ref | 4 (44.4) | Ref | 7 (77.8) | ||||
| Normal weight (18.5‐24.9) | 242 (71.0%) | 55 (22.7) | 3.08 (0.35, 27.31) | 49 (20.3) | 0.32 (0.07, 1.31) | 132 (54.6) | 0.41 (0.08, 2.06) | |||
| Overweight (25.0‐29.9) | 79 (23.2%) | 24 (30.4) | 4.72 (0.51, 43.95) | 25 (31.7) | 0.63 (0.14, 2.76) | 55 (69.6) | 0.80 (0.15, 4.26) | |||
| Obesity (≥30) | 11 (3.3%) | 3 (27.3) | .421 | 2.83 (0.22, 37.14) | 3 (27.3) | .087 | 0.47 (0.07, 3.23) | 7 (63.6) | .07 | 0.56 (0.07, 4.21) |
| Menopausal status | ||||||||||
| Regular menstrual | 10 (3.7%) | 4 (40.0) | Ref | 0 (0) | Ref | 8 (66.7) | Ref | |||
| Irregular menstrual | 20 (7.4%) | 10 (50.0) | 0.89 (0.17, 4.65) | 6 (30) | — | 16 (76.2) | 1.20 (0.20, 7.30) | |||
| Postmenopausal | 242 (89.0%) | 56 (23.1) |
| 0.54 (0.14, 2.16) | 61 (25.2) | .164 | — | 177 (57.5) | .207 | 0.59 (0.14, 2.46) |
| Self‐reported general health status | ||||||||||
| Bad/very bad | 32 (9.4%) | 4 (12.5) | Ref | 13 (40.6) | Ref | 21 (65.6) | Ref | |||
| Fair | 206 (60.6%) | 42 (20.3) | 1.68 (0.54, 5.16) | 45 (21.7) |
| 125 (60.4) | 0.75 (0.34, 1.68) | |||
| Good/very good | 102 (30.0%) | 37 (36.3) |
|
| 23 (22.6) | .061 |
| 55 (53.9) | .400 | 0.51 (0.21, 1.19) |
| Cancer‐related characteristics | ||||||||||
| Stagec | ||||||||||
| 0‐I | 115 (37.8%) | 24 (20.9) | Ref | 25 (21.7) | Ref | 64 (55.7) | Ref | |||
| II | 140 (46.1%) | 43 (30.7) | 1.54 (0.84, 2.82) | 39 (27.9) | 1.39 (0.77, 2.52) | 90 (64.3) | 1.32 (0.79, 2.21) | |||
| III‐IV | 49 (16.1%) | 9 (18.4) | .098 | 0.78 (0.32, 1.90) | 9 (18.4) | .314 | 0.78 (0.33, 1.86) | 27 (55.1) | .297 | 0.93 (0.47, 1.84) |
| Time since diagnosis (y) | ||||||||||
| <3 | 115 (33.7%) | 30 (26.1) | 25 (21.7) | 72 (62.6) | ||||||
| ~3 | 132 (38.7%) | 30 (22.7) | 0.79 (0.43, 1.47) | 41 (31.1) | 1.71 (0.94, 3.09) | 76 (57.6) | 0.88 (0.52, 1.49) | |||
| ≥5 | 94 (27.6%) | 23 (24.5) | .828 | 1.19 (0.61, 2.23) | 15 (16.0) |
| 0.67 (0.32, 1.40) | 53 (56.4) | .608 | 0.85 (0.48, 1.52) |
| Surgery type | ||||||||||
| Lumpectomy | 39 (11.4%) | 14 (35.9) | Ref | 7 (18.0) | Ref | 20 (51.3) | Ref | |||
| Mastectomy | 302 (88.6%) | 69 (22.9) | .074 | 0.51 (0.24, 1.11) | 74 (24.5) | .365 | 1.89 (0.78, 4.57) | 181 (59.9) | .301 | 1.49 (0.75, 2.94) |
| Breast reconstructione | ||||||||||
| Yes | 8 (2.7%) | 4 (50.0) | Ref | 2 (25.0) | Ref | 5 (62.5) | Ref | |||
| No | 294 (97.4%) | 65 (22.2) | .081 | 0.38 (0.09, 1.70) | 72 (24.9) | .316 | 0.98 (0.19, 5.20) | 176 (59.9) | .999 | 1.06 (0.25, 4.60) |
| Radiotherapy | ||||||||||
| No | 225 (66.0%) | 55 (24.4) | Ref | 56 (24.9) | Ref | 129 (57.3) | Ref | |||
| Yes | 116 (34.0%) | 28 (24.1) | .95 | 0.81 (0.46, 1.40) | 25 (21.6) | .492 | 0.77 (0.44, 1.34) | 72 (62.1) | .399 | 1.14 (0.72, 1.83) |
| Chemotherapy | ||||||||||
| No | 51 (15.0%) | 11 (21.6) | Ref | 12 (23.5) | Ref | 23 (45.1) | Ref | |||
| Yes | 290 (85.0%) | 72 (24.8) | .617 | 1.09 (0.52, 2.32) | 69 (23.8) | .967 | 1.08 (0.53, 2.22) | 178 (61.4) |
|
|
| Hormonal therapy | ||||||||||
| Never | 125 (36.7%) | 25 (20) | Ref | 32 (25.6) | Ref | 72 (57.6) | Ref | |||
| Ever | 33 (9.7%) | 9 (27.3) | 1.68 (0.66, 4.32) | 7 (21.2) | 1.00 (0.38, 2.65) | 17 (51.5) | 0.82 (0.37, 1.82) | |||
| Current | 183 (53.6%) | 49 (26.8) | .364 | 1.44 (0.81, 2.54) | 42 (23.0) | .811 | 0.81 (0.47, 1.39) | 112 (61.2) | .54 | 1.13 (0.70, 1.81) |
| Recurrance | ||||||||||
| No | 331 (97.1%) | 82 (24.8) | Ref | 80 (24.2) | Ref | 196 (59.2) | Ref | |||
| Yes | 10 (2.9%) | 1 (10.0) | .284 | 0.33 (0.04, 2.79) | 1 (10.0) | .299 | 0.36 (0.04, 3.03) | 5 (50.0) | .56 | 0.78 (0.21, 2.84) |
| Metastasis | ||||||||||
| No | 323 (94.7%) | 79 (24.5) | Ref | 76 (23.5) | Ref | 188 (58.2) | Ref | |||
| Yes | 18 (5.3%) | 4 (22.2) | .83 | 0.71 (0.21, 2.35) | 5 (27.8) | .68 | 1.24 (0.41, 3.77) | 13 (72.2) | .239 | 2.15 (0.72, 6.42) |
All models were adjusted for age, marital status, self‐reported general health status, and time since cancer diagnosis.
Bold face P < .05.
Abbreviations: AOR, adjusted odds ratio; BC, breast cancer.
Chi‐square test or Fisher's exact test.
Analysis restricted to individuals aged 45‐64 y (n = 272). BC deemed to be postmenopausal when they had not menstruated in the past year.
Cancer stage was unknown for 37 subjects. Stage 0‐Ⅰ groups include 10 subjects with stage 0 and 105 subjects with stage Ⅰ. Stage Ⅲ‐Ⅳ groups include 44 subjects with stage Ⅲ and 5 subjects with stage Ⅳ.
Subjucts who received their cancer diagnosis <3 y (n = 115) includes 2 subjects with cancer diagnosis <1 y and 113 subjects with cancer diagnosis 1‐3 y.
Analysis restricted to individuals with mastectomy (n = 302).
Reporting of sexual activity, sexual dissatisfaction, and BC decreased their sexual activity frequency in relation to comorbid chronic diseases
| Comorbidity | Total | Sexual activity | Sexual dissatisfaction | BC decreased their sexual activity frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) |
| AOR | N (%) |
| AOR | N (%) |
| AOR | ||
| Hypertension | ||||||||||
| No | 247 (72.4%) | 66 (26.7) | Ref | 59 (23.9) | Ref | 142 (57.5) | Ref | |||
| Yes | 94 (27.6%) | 17 (18.1) | .097 | 0.59 (0.29, 1.17) | 22 (23.4) | .926 | 1.23 (0.62, 2.43) | 59 (62.8) | .376 | 1.46 (0.83, 2.58) |
| Hyperlipidemia | ||||||||||
| No | 239 (70.1%) | 63 (26.4) | Ref | 61 (25.5) | Ref | 143 (59.8) | Ref | |||
| Yes | 102 (29.9%) | 20 (19.6) | .183 | 0.71 (0.35, 1.43) | 20 (19.6) | .24 | 0.71 (0.35, 1.45) | 58 (56.9) | .61 | 0.88 (0.49, 1.56) |
| Hyperuricemia | ||||||||||
| No | 325 (95.3%) | 82 (25.2) | Ref | 75 (23.1) | Ref | 193 (59.4) | Ref | |||
| Yes | 16 (4.7%) | 1 (6.3) | .084 | 0.21 (0.02, 1.71) | 6 (37.5) | .186 | 1.97 (0.61, 6.42) | 8 (50.0) | .456 | 0.65 (0.22, 1.95) |
| Diabetes mellitus | ||||||||||
| No | 307 (90.0%) | 81 (26.4) | Ref | 68 (22.2) | Ref | 182 (59.3) | Ref | |||
| Yes | 34 (10.0%) | 2 (5.9) |
|
| 13 (38.2) |
|
| 19 (55.9) | .702 | 0.90 (0.41, 1.95) |
| Heart and cardiovascular | ||||||||||
| No | 298 (87.4%) | 71 (23.8) | Ref | 69 (23.2) | Ref | 171 (57.4) | Ref | |||
| Yes | 43 (12.6%) | 12 (27.9) | .559 | 1.70 (0.75, 3.88) | 12 (27.9) | .494 | 1.61 (0.72, 3.63) | 30 (69.8) | .123 | 2.05 (0.96, 4.39) |
| Stroke | ||||||||||
| No | 334 (98.0%) | 81 (24.3) | Ref | 78 (23.4) | Ref | 196 (58.7) | Ref | |||
| Yes | 7 (2.1%) | 2 (28.6) | .792 | 1.84 (0.33, 10.12) | 3 (42.9) | .23 | 3.18 (0.65, 15.58) | 5 (71.4) | .497 | 1.75 (0.32, 9.48) |
| Respiratory diseases | ||||||||||
| No | 309 (90.6%) | 74 (24.0) | Ref | 76 (24.6) | Ref | 182 (58.9) | Ref | |||
| Yes | 32 (9.4%) | 9 (28.1) | .6 | 1.47 (0.59, 3.66) | 5 (15.6) | .256 | 0.54 (0.19, 1.54) | 19 (59.4) | .958 | 1.08 (0.49, 2.41) |
| Digestive diseases | ||||||||||
| No | 186 (54.6%) | 43 (23.1) | Ref | 49 (26.3) | Ref | 115 (61.8) | Ref | |||
| Yes | 155 (45.5%) | 40 (25.8) | .565 | 1.20 (0.61, 2.40) | 32 (20.7) | .218 | 0.88 (0.43, 1.78) | 86 (55.5) | .236 | 0.67 (0.37, 1.21) |
| Musculoskeletal diseases | ||||||||||
| No | 291 (85.3%) | 71 (24.4) | Ref | 66 (22.7) | Ref | 175 (60.1) | Ref | |||
| Yes | 50 (14.7%) | 12 (24.0) | .952 | 1.23 (0.55,2.79) | 15 (30.0) | .261 | 1.81 (0.83,3.93) | 26 (52.0) | .279 | 0.71 (0.36,1.41) |
| Number of comorbidity | ||||||||||
| 0‐1 | 184 (53.9%) | 53 (28.8) | Ref | 41 (22.3) | Ref | 112 (60.9) | Ref | |||
| 2‐3 | 125 (36.7%) | 24 (19.2) | 0.83 (0.45, 1.53) | 31 (24.8) | 1.17 (0.65, 2.11) | 71 (56.8) | 0.93 (0.57, 1.54) | |||
| ≥4 | 32 (9.4%) | 6 (18.8) | .115 | 0.91 (0.33, 2.47) | 9 (28.1) | .729 | 1.56 (0.64, 3.85) | 18 (56.3) | .735 | 1.05 (0.47, 2.33) |
All models were adjusted for age, marital status, self‐reported general health status, and time since cancer diagnosis.
Models investigating each specific comorbid chronic disease were also adjusted for the number of comorbidity.
Bold face P < .05.
Abbreviations: AOR, adjusted odds ratio; BC, breast cancer.
Chi‐square test or Fisher's exact test.
Reporting of sexual activity, sexual dissatisfaction, and BC decreased their sexual activity frequency in relation to psychologic variables and body image
| Psychologic variables | Total | Sexual activity | Sexual dissatisfaction | BC decreased their sexual activity frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N (%) |
| AOR | N (%) |
| AOR | N (%) |
| AOR | ||
| Anxiety | ||||||||||
| No | 237 (69.5%) | 57 (24.1) | 55 (23.2) | 135 (57.0) | ||||||
| Yes | 104 (30.5%) | 26 (25.0) | .851 | 1.25 (0.71, 2.22) | 26 (25.0) | .72 | 1.06 (0.61, 1.87) | 66 (63.5) | .261 | 1.29 (0.79, 2.11) |
| Depression | ||||||||||
| No | 196 (57.5%) | 49 (25.0) | 41 (20.9) | 109 (55.6) | ||||||
| Yes | 145 (42.5%) | 34 (23.5) | .741 | 1.00 (0.59, 1.72) | 40 (27.6) | .153 | 1.39 (0.82, 2.35) | 92 (63.5) | .146 | 1.28 (0.81, 2.02) |
| Felt physically less attractive as a result of your disease or treatment | ||||||||||
| No | 142 (41.6%) | 34 (23.9) | 24 (16.9) | 72 (50.7) | ||||||
| Yes | 199 (58.4%) | 49 (24.6) | .885 | 1.31 (0.75, 2.28) | 57 (28.6) |
|
| 129 (64.8) |
|
|
| Find it difficult to look at yourself naked | ||||||||||
| No | 122 (35.8%) | 35 (28.7) | 28 (23.0) | 66 (54.1) | ||||||
| Yes | 219 (64.2%) | 48 (21.9) | .163 | 0.82 (0.47, 1.41) | 53 (24.2) | .795 | 1.01 (0.58, 1.73) | 135 (61.6) | .175 | 1.29 (0.81, 2.05) |
| Feeling less feminine as a result of your disease or treatment | ||||||||||
| No | 140 (41.1%) | 35 (25.0) | 25 (17.9) | 65 (46.4) | ||||||
| Yes | 201 (58.9%) | 48 (23.9) | .813 | 1.02 (0.59, 1.75) | 56 (27.9) |
|
| 136 (67.7) |
|
|
| Dissatisfied with your body | ||||||||||
| No | 150 (44.0%) | 40 (26.7) | 30 (20.0) | 78 (52.0) | ||||||
| Yes | 191 (56.0%) | 43 (22.5) | .375 | 1.05 (0.60, 1.82) | 51 (26.7) | .149 | 1.40 (0.80, 2.46) | 123 (64.4) |
|
|
All models were adjusted for age, marital status, self‐reported general health status, and time since cancer diagnosis. Bold face P < .05.
Abbreviations: AOR, adjusted odds ratio; BC, breast cancer.
Chi‐square test or Fisher's exact test.
Reporting of sexual activity, sexual dissatisfaction, and BC decreased their sexual activity frequency in relation to sexual partner and individual's sexual attitude
| The sexual attitude of BCS and their partner | Total N (%) | Sexual activity | Sexual dissatisfaction | BC decreased their sexual activity frequency | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Yes N (%) |
| AOR |
Yes N (%) |
| AOR |
Yes N (%) |
| AOR | ||
|
| ||||||||||
| Without sexual partner | ||||||||||
| No | 258 (75.6) | 69 (26.9) | Ref | 56 (21.7) | Ref | 148 (57.4) | Ref | |||
| Yes | 83 (24.4) | 14 (16.9) | .067 | 0.55 (0.28, 1.07) | 25 (30.1) | .117 | 1.66 (0.93, 2.95) | 53 (63.9) | .296 | 1.26 (0.75, 2.12) |
| Partner lacking of sexual interest | ||||||||||
| No | 183 (59.4) | 58 (31.7) | Ref | 41 (22.4) | Ref | 108 (59.0) | Ref | |||
| Yes | 125 (40.6) | 19 (15.2) |
|
| 28 (22.4) | .999 | 1.01 (0.57, 1.78) | 74 (59.2) | .974 | 1.11 (0.69, 1.80) |
| Partner' poor health condition | ||||||||||
| No | 223 (72.4) | 65 (29.2) | Ref | 41 (18.4) | Ref | 129 (57.9) | Ref | |||
| Yes | 85 (27.6) | 12 (14.1) |
|
| 28 (32.9) |
|
| 58 (64.2) | .472 | 1.33 (0.77, 2.29) |
| Partner feeling too tired | ||||||||||
| No | 213 (69.1) | 59 (27.7) | Ref | 41 (19.3) | Ref | 119 (55.9) | Ref | |||
| Yes | 95 (30.8) | 18 (19.0) | .101 | 0.72 (0.39, 1.35) | 28 (29.5) |
| 1.79 (0.99, 3.22) | 63 (66.3) | .085 | 1.61 (0.95, 2.72) |
| Partner not initiating a sexual activity | ||||||||||
| No | 186 (60.4) | 68 (36.6) | Ref | 68 (36.6) | Ref | 103 (55.4) | Ref | |||
| Yes | 122 (39.6) | 9 (7.4) |
|
| 9 (7.4) |
|
| 79 (64.8) | .102 | 1.54 (0.94, 2.52) |
|
| ||||||||||
| Partner fear contracting cancer by sexual activity | ||||||||||
| No | 232 (75.3) | 66 (28.5) | Ref | 51 (22.0) | Ref | 133 (57.3) | Ref | |||
| Yes | 76 (24.7) | 11 (14.5) |
|
| 18 (23.7) | .758 | 1.11 (0.59, 2.08) | 49 (64.5) | .272 | 1.31 (0.76, 2.29) |
| Sexual activity may weaken treatment effects | ||||||||||
| No | 125 (36.7) | 38 (30.4) | Ref | 24 (19.2) | Ref | 55 (44.0) | Ref | |||
| Yes | 216 (63.3) | 45 (20.8) |
| 0.61 (0.36, 1.05) | 57 (26.4) | .132 | 1.65 (0.93, 2.91) | 146 (67.6) |
|
|
| Sexual activity may impede disease recovery | ||||||||||
| No | 125 (36.7) | 41 (32.8) | Ref | 23 (18.4) | Ref | 54 (43.2) | Ref | |||
| Yes | 216 (63.3) | 42 (19.4) |
|
| 58 (26.9) | .077 |
| 147 (68.1) |
|
|
| Sexual activity may cause cancer recurrence or metastasizes | ||||||||||
| No | 131 (38.4) | 42 (32.1) | Ref | 21 (16.0) | Ref | 57 (45.3) | Ref | |||
| Yes | 210 (61.6) | 41 (19.5) |
|
| 60 (28.6) |
|
| 144 (68.6) |
|
|
| Sexual activity could change the estrogen level and stimulate tumor growth | ||||||||||
| No | 154 (45.2) | 43 (31.5) | Ref | 28 (18.2) | Ref | 74 (48.1) | Ref | |||
| Yes | 187 (54.8) | 50 (26.7) | .807 | 0.97 (0.59, 1.42) | 53 (28.3) |
|
| 127 (67.9) |
|
|
Bold face P < .05.
AOR: adjusted odds ratio, adjusted for age, marital status, self‐reported general health status, and time since cancer diagnosis.
Analysis restricted to individuals married/cohabiting (n = 308).